<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title>health++ team - health++</title><description>Thoughts, stories and ideas.</description><link>http://localhost:2368/</link><generator>Ghost 0.5</generator><lastBuildDate>Mon, 09 Feb 2015 07:59:16 GMT</lastBuildDate><atom:link href="http://localhost:2368/author/health/rss/" rel="self" type="application/rss+xml"/><ttl>60</ttl><item><title>Incentives and Financial Returns</title><description>&lt;p&gt;This week we tackled the area of financial returns in investing in healthcare startups, Evan posed to us the question:&lt;/p&gt;

&lt;blockquote&gt;
  &lt;p&gt;Are the financial returns for investing in a healthcare startup less than a technology startup?  Why?  If the perception is that they are less, how can that be changed?&lt;/p&gt;
&lt;/blockquote&gt;

&lt;p&gt;In response, we tried to pinpoint various reasons why the barrier to entry in healthcare innovation is so high:&lt;/p&gt;

&lt;ul&gt;
&lt;li&gt;Higher risk in healthcare than technology ventures&lt;/li&gt;
&lt;li&gt;Larger startup costs&lt;/li&gt;
&lt;li&gt;Rules + Regulations&lt;/li&gt;
&lt;li&gt;Depth of knowledge required&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Evan Anderson&lt;/strong&gt;, a 2004 graduate of the &lt;a href="http://biodesign.stanford.edu/bdn/index.jsp"&gt;Stanford Biodesign&lt;/a&gt; program previously worked at &lt;a href="http://spiracur.com/"&gt;Spiracur&lt;/a&gt; and the FDA. He currently works as a medical device consultant and is in the process of starting a new venture in dermatology.&lt;/p&gt;</description><link>http://localhost:2368/think-tank-1-evan-anderson/</link><guid isPermaLink="false">7eed5811-9190-4535-b161-ebe0e698836d</guid><category>thinktank</category><dc:creator>health++ team</dc:creator><pubDate>Mon, 09 Feb 2015 05:56:59 GMT</pubDate></item></channel></rss>